End-to-End Genomic Analysis
-
Enabling fast, accurate, secure, low cost and scalable genomic analysis, on easy-to-use standalone appliances.
-
Empowering researchers and clinicians to explore and run their own custom methodologies
Our Mission
Deliver an affordable Precision Medicine healthcare future that
touches and enriches the lives of everyone...
NCCHD in Japan Demonstrates Improved Diagnostics Rate for Rare Disease Diagnostics using OmniTier’s CompStor® Genomic Analysis Platform
Benchmark WES re-analysis study with OmniTier’s AI-based variant interpretation platform achieves around a 42% diagnostics rate, a 7% improvement in the average rate for diagnosing rare diseases
“Achieving highly accurate diagnostics for rare genetic diseases is vital for us in pediatric healthcare. We are very pleased to achieve the significant increase in the diagnostics rate for our methodology using OmniTier’s powerful variant interpretation platform,” said Dr. Tadashi Kaname, Director of Genome Medicine at NCCHD. READ MORE
Why choose OmniTier for my genomic analysis?
- On-premise analysis appliances provide lower cost analysis, greater control over patient data and large, data storage cost-savings.
- Supports Illumina, MGI Tech, Oxford Nanopore Technology and PacBio sequencing.
- Two variant callers; higher quality, proprietary, Novos variant caller, as well as standard Broad Institute (GATK) variant caller; SNPs, indels, structural variants, copy number variants and mitochondrial. Identifies more true-positives and returns fewer false-positive variants.
- Reduces days of secondary analysis and variant interpretation into minutes through automation and AI technology.
- Built to scale, from analyzing a few exomes up to thousands of whole genomes. Your OmniTier infrastructure can scale up as your analytics volumes grow.
- End-to-end, easy to use, built-in analysis workflows. Designed for researchers, clinicians and bioinformaticians, rather than IT and software specialists.
- Targeting low to high volume clinical research diagnostics and screening.
Designed to meet the needs of…
News & Updates
View All
OmniTier exhibiting at ASHG, Washington DC - Nov 2nd-4th, 2023
OmniTier announced that it will be exhibiting at ASHG2023 in Washington DC, between November 2nd-4th. OmniTier will be providing demonstrations of its leading on-premise, genomics analysis appliances; CompStor Novos secondary analysis with built in analysis for all major short read and long read sequencers, as well as CompStor Insight variant interpretation.
OmniTier unveils the industry’s first on-premise, standalone, end-to-end genomic analysis appliance, at cost below $50 per WGS sample, at scale
SAN JOSE, CA. USA, April 18, 2023: OmniTier Inc, a leader in on-premise genomics analysis products, today launched the industry’s first on-premise, standalone appliance for both human genomic data analysis (secondary analysis) and biomedical data interpretation (tertiary analysis), called CompStor Spectrum.
NCCHD in Japan Demonstrates Improved Diagnostics Rate for Rare Disease Diagnostics using OmniTier’s CompStor® Genomic Analysis Platform
San Jose CA, USA: February 2, 2023 – Benchmark WES re-analysis study with OmniTier’s AI-based variant interpretation platform achieves around a 42% diagnostics rate, a 7% improvement in the average rate for diagnosing rare diseases